Chemistry: analytical and immunological testing – Clotting or clotting factor level tests
Reexamination Certificate
2006-12-07
2010-06-08
Wallenhorst, Maureen M (Department: 1797)
Chemistry: analytical and immunological testing
Clotting or clotting factor level tests
C436S063000, C422S073000, C435S013000, C600S368000, C600S369000, C073S064410
Reexamination Certificate
active
07732213
ABSTRACT:
A hemostasis analyzer, such as the Thrombelastograph® (TEG®) hemostasis analyzer is utilized to measure continuously in real time, the hemostasis process from the initial fibrin formation, through platelet-fibrin interaction and lysis to generate blood hemostasis parameters. The measured blood hemostasis parameters permit evaluation of a patient hemostasis condition.
REFERENCES:
patent: 3714815 (1973-02-01), Hartert
patent: 4148216 (1979-04-01), Do et al.
patent: 4193293 (1980-03-01), Cavallari
patent: 4312217 (1982-01-01), Hartert
patent: 4317363 (1982-03-01), Shen
patent: 4328701 (1982-05-01), Mau-Tung et al.
patent: 4695956 (1987-09-01), LeVeen et al.
patent: 5167145 (1992-12-01), Butler et al.
patent: 5223227 (1993-06-01), Zuckerman
patent: 5466582 (1995-11-01), Amiral
patent: 5523238 (1996-06-01), Varon et al.
patent: 5777215 (1998-07-01), Calatzis et al.
patent: 5854423 (1998-12-01), Venegas
patent: 5939276 (1999-08-01), Tomer
patent: 5972712 (1999-10-01), Baugh et al.
patent: 5972717 (1999-10-01), Aster et al.
patent: 6017890 (2000-01-01), Hoekstra et al.
patent: 6027904 (2000-02-01), Devine et al.
patent: 6060323 (2000-05-01), Jina
patent: 6225126 (2001-05-01), Cohen et al.
patent: 6410337 (2002-06-01), Brady et al.
patent: 6537819 (2003-03-01), Cohen et al.
patent: 6613573 (2003-09-01), Cohen
patent: 7179652 (2007-02-01), Cohen et al.
patent: 7211438 (2007-05-01), Toh et al.
patent: 7235377 (2007-06-01), Mann et al.
patent: 2002/0178126 (2002-11-01), Beck et al.
patent: 2002/0197697 (2002-12-01), Abdelouahed et al.
patent: 2002/0198740 (2002-12-01), Roman et al.
patent: 37 38 901 (1989-05-01), None
patent: 0 018 905 (1980-12-01), None
patent: 0 404 456 (1990-12-01), None
patent: 0 525 273 (1991-02-01), None
patent: 1 226 781 (2002-07-01), None
patent: 1 371 981 (2003-02-01), None
patent: 2 389 137 (1978-11-01), None
patent: 2 004 376 (1979-03-01), None
patent: WO-97/41432 (1997-11-01), None
patent: WO-00/49402 (2000-08-01), None
patent: WO-01/04159 (2001-01-01), None
patent: WO-01/50950 (2001-07-01), None
patent: WO-01/96879 (2001-12-01), None
patent: WO-02/054088 (2002-07-01), None
patent: WO-2004/092742 (2004-10-01), None
Gaetano at al., Effect of Platelets on Clot Structuration. A Thromebelastographic Study. Thrombosis Research. vol. 3, 1973, pp. 425-435.
Greilich et al. A Modified Thromboelastographic Method for Monitoring c7E3 Fab in Heparinized Patients. Anesth Analg., vol. 84, 1997, pp. 31-38.
Khurana et al., Monitoring Platelet Glycoprotein IIb/IIIa-fibrin Interation With Tissue Factor-Activated Thromboelastography. J Lab Clin Med, 1997, pp. 401-411.
Timmis et al., Advances in Antiplatelet Therapy in Coronary Artery Disease: Importance of the Platelet GPIIb/IIIa Receptor. Journal of Interventional Cardiology, vol. 10, No. 5, 1997, pp. 327-333.
Ultegra Rapid Platelet Function Assay (RPFA) Bedside Monitoring, Cath-Lab Digest, vol. 7, No. 6, 1999, pp. 1-3.
Ultegra System, Accumetrics Brochure, 2 pages.
Dambisya at al., Effects of the Platelet-Activating Factor Receptor Antagonist Web 2086 on Whole Blood Coagulation and Fibrinolysis in a Thromboelastography Assay. Blood Coagulation and Fibrinolysis, vol. 6, 1995, pp. 733-737.
CSA Clot Signature Analyzer—Global Screening Device for Hemostasis, Xylum Corporation, 4 pages.
Orbitometer—The consequent development of the precursory Thrombo-Elastography (Hartert 1947) and of Resonance-Thrombography (Hartert 1977), Heinrich Amelung GmbH, 6 pages.
RoTEG Coagulation Analyzer, 1997 Dynabyte Medical, 2 pages.
RoTEG Coagulation Analyzer—whole blood coagulation analysis, 4 pages.
Eivi 816—Dual Channel, B1 Clot Thromboelastograph, Logos Scientific Inc., 2 pages.
TE-700—New Type Clot-Tracer Model, Erima, 4 pages (Japanese translation), 2 pages (English translation).
Muhl T al., “Therapy and Monitoring of Heparin-Induced Thrombocytopenia Type II in Critically Ill Patients During Continuous Venovenous Hemodiafiltration: Comparison of aPTT and Ecarin Clotting Time for Monitoring of r-Hirudin Therapy,” Journal of Intensive Care Medicine, vol. 17, No. 1, Jan./Feb. 2002, pp. 34-40.
Koster et al., “Recombinant Hirudin as an Alternative for Anticoagulation During Cardiopulmonary Bypass in Patients with Heparin-Induced Thrombocytopenia Type II: A 1-Year Experience in 57 Patients,” Journal of Cardiothoracic and Vascular Anesthesia, vol. 14, No. 3, Jun. 2000, pp. 243-248.
Frenette et al., Effectiveness of Conjugated Estrogen in Orthotopic Liver Transplantation, Southern Medical Journal, vol. 91, Apr. 1998, pp. 365-368.
Ammar et al., “In Vitro Effects of the Platelet Glycoprotein IIb/IIIa Receptor Antagonist c7E3 Fab on the Activated Clotting Time,” Circulation, vol. 95, No. 3, Feb. 4, 1997, pp. 614-617.
Shore-Lesserson et al., Thromboelastography-Guided Transfusion Algorithm Reduces Transfusions in Complex Cardiac Surgery, Anesthesia and Analgesis (abstract), Feb. 1999, 1 page.
Nguyen et al., A Web-Based Teaching Program for Laboratory Diagnosis of Coagulation Disorders, Arch. Pathol, Lab. Med., vol. 124, Apr. 2000, pp. 588-593.
Edwards et al., “Successful Use of Argatroban as a Heparin Substitute During Cardiopulmonary Bypass: Heparin-Induced Thrombocytopenia in a High-Risk Cardiac Surgical Patient,” The Annals of Thoracic Surgery, vol. 75, No. 5, May 2003, pp. 1622-1624.
Cohen Eli
Cohen Roslyn
Anthony G. Sitko PLC
CoraMed Healthcare, Inc.
Wallenhorst Maureen M
LandOfFree
Method of evaluating patient hemostasis does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of evaluating patient hemostasis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of evaluating patient hemostasis will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4193835